WO2013058482A3 - 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물 - Google Patents

표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물 Download PDF

Info

Publication number
WO2013058482A3
WO2013058482A3 PCT/KR2012/007603 KR2012007603W WO2013058482A3 WO 2013058482 A3 WO2013058482 A3 WO 2013058482A3 KR 2012007603 W KR2012007603 W KR 2012007603W WO 2013058482 A3 WO2013058482 A3 WO 2013058482A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
therapy
nucleic acid
cancer drug
same
Prior art date
Application number
PCT/KR2012/007603
Other languages
English (en)
French (fr)
Other versions
WO2013058482A2 (ko
Inventor
엄숭호
김아라
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Priority to US14/352,211 priority Critical patent/US9163048B2/en
Publication of WO2013058482A2 publication Critical patent/WO2013058482A2/ko
Publication of WO2013058482A3 publication Critical patent/WO2013058482A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 5'말단에 티올기를 가지고 있는 선형핵산에 항암제를 물리적으로 결합시키고, 이후 금 나노입자, 압타머를 화학적으로 결합시킨 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물에 관한 것이다. 본 발명에 따른 다기능성 핵산 기반 항암제는 A10 압타머의 사용으로 높은 표적지향성을 가지며, 고농축 항암제와 금 나노입자의 사용으로 열 치료/화학 치료의 이중 치료법(dual therapy)이 가능하여, 기존의 항암제에 비하여 낮은 부작용, 높은 항암 치료 효과 등을 가진다.
PCT/KR2012/007603 2011-10-17 2012-09-21 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물 WO2013058482A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/352,211 US9163048B2 (en) 2011-10-17 2012-09-21 Multi-functional nucleic acid-based anti-cancer drug capable of targeting and therapy, method for preparing same and anti-cancer composition comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0105947 2011-10-17
KR1020110105947A KR101337684B1 (ko) 2011-10-17 2011-10-17 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물

Publications (2)

Publication Number Publication Date
WO2013058482A2 WO2013058482A2 (ko) 2013-04-25
WO2013058482A3 true WO2013058482A3 (ko) 2013-06-27

Family

ID=48141507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007603 WO2013058482A2 (ko) 2011-10-17 2012-09-21 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물

Country Status (3)

Country Link
US (1) US9163048B2 (ko)
KR (1) KR101337684B1 (ko)
WO (1) WO2013058482A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103263673B (zh) * 2013-06-07 2015-02-25 南开大学 一种多糖—金纳米粒子超分子组装体及其制备方法和应用
KR101537474B1 (ko) 2014-04-18 2015-07-16 성균관대학교산학협력단 고효율 자가발광 나노복합체, 이의 제조방법 및 이를 포함하는 항암용 조성물
CN104865216A (zh) * 2015-06-10 2015-08-26 常熟理工学院 一种基于纳米金核酸适配体比色检测氯霉素的方法
EP3332812A1 (en) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid-based assembly and use of the assembly in cancer therapy
KR102205032B1 (ko) 2018-10-25 2021-01-19 (주)에스비바이오사이언스 면역 검출용 접합체 및 이를 사용한 면역 검출 방법
KR102336120B1 (ko) * 2019-06-05 2021-12-08 주식회사 엔이에스바이오테크놀러지 금 나노입자-앱타머 결합체를 기반으로 하는 항체 전달체 및 이의 제조 방법
KR20210061293A (ko) * 2019-11-19 2021-05-27 주식회사 바이오이즈 압타머 기반 표적화 복합 항암제
WO2021187902A1 (ko) * 2020-03-18 2021-09-23 김성천 핵산 기반 항암제
KR102221169B1 (ko) 2021-01-05 2021-02-26 주식회사 에스비바이오사이언스 단일 가닥 dna 결합 단백질과 신호발생물질이 결합된 접합체를 포함하는 면역 검출 키트 및 이를 사용한 면역 검출 방법
KR102221168B1 (ko) 2021-01-05 2021-02-26 주식회사 에스비바이오사이언스 인플루엔자 a 바이러스 검출용 접합체 및 이를 사용한 인플루엔자 a 바이러스 검출 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20110237652A1 (en) * 2008-10-15 2011-09-29 Ron Weiss Detection and destruction of cancer cells using programmed genetic vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
US8058415B2 (en) * 2007-04-24 2011-11-15 The Board Of Trustees Of The University Of Illinois Aptamer- and nucleic acid enzyme-based systems for simultaneous detection of multiple analytes
US8927509B2 (en) * 2008-05-20 2015-01-06 The Research Foundation Of State University Of New York Aptamer modulators of complement protein C3 and biologically active proteolytic products thereof
US8871509B2 (en) * 2009-11-06 2014-10-28 Chung-Ang University-Academy Corporation Foundation Nanoparticle-based gene delivery systems
EP2635262A4 (en) * 2010-11-01 2016-05-25 Univ Syracuse SYSTEM AND METHOD FOR THE ADMINISTRATION OF DNA BINDING CHEMOTHERAPY DRUGS USING NANOPARTICLES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20110237652A1 (en) * 2008-10-15 2011-09-29 Ron Weiss Detection and destruction of cancer cells using programmed genetic vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIH-CHING HUANG ET AL.: "Aptamer-Modified Gold Nanoparticles for Colorimetric Determination of Platelet-Derived Growth Factors and Their Receptors.", ANALYTICAL CHEMISTRY, vol. 77, no. 17, 2005, pages 5735 - 5741 *
YU-FEN HUANG ET AL.: "Aptamer-modified gold nanoparticles for targeting breast cancer cells through light scattering.", JOURNAL OF NANOPARTICLE RESEARCH., vol. 11, no. 4, May 2009 (2009-05-01), pages 775 - 783, XP019685122 *

Also Published As

Publication number Publication date
US9163048B2 (en) 2015-10-20
WO2013058482A2 (ko) 2013-04-25
KR20130041591A (ko) 2013-04-25
KR101337684B1 (ko) 2013-12-30
US20140350230A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
WO2013058482A3 (ko) 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2012170889A8 (en) Cleavable lipids
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2013028942A8 (en) Targeting microbubbles
MX2023008180A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
WO2012006380A3 (en) Cationic oil-in-water emulsions
WO2012110636A3 (en) Carrier peptides for cell delivery
WO2011133925A3 (en) Targeted and light-activated cytosolic drug delivery
WO2012006376A3 (en) Virion-like delivery particles for self-replicating rna molecules
WO2011139911A3 (en) Lipid formulated single stranded rna
WO2012106713A3 (en) Targeted nanoparticle conjugates
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
SG195194A1 (en) Nanogels
WO2012149440A3 (en) Therapeutic nuclease compositions and methods
WO2011009539A8 (de) ε-POLYLYSIN-KONJUGATE UND DEREN VERWENDUNG
WO2012116073A3 (en) Amphiphilic dendron-coils, micelles thereof and uses
WO2009129387A3 (en) Cationic lipids and uses thereof
EP4328314A3 (en) Lipid nanoparticle methods and compositions for producing engineered erythroid cells
WO2012010974A3 (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2012040331A3 (en) Multistage nanoparticles
WO2014070687A3 (en) Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells
WO2012007845A3 (en) A method of increasing the effect of an activated-potentiated form of an antibody
WO2011107866A3 (en) Silyl-derivatives of polysaccharides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12841058

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14352211

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12841058

Country of ref document: EP

Kind code of ref document: A2